Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium Pharmaceutical reported record Q3 2026 net product revenue of $216.3 million, up 3% year over year, as ADHD revenue grew and rose to 36% of the revenue mix from 19% a year earlier. Jornay PM revenue increased 24% to $51.9 million, while the pain portfolio fell 18% to $138.0 million, including a 44% decline in Nucynta franchise revenue amid generic competition. Adjusted EBITDA decreased 9% to $121.6 million; management reaffirmed 2026 revenue guidance of $825 million-$855 million and adjusted EBITDA guidance of $445 million-$470 million, and began a $50 million accelerated share repurchase.

Analysis

The key debate is whether ADHD growth is durable enough to offset a structurally shrinking pain franchise—not whether the quarter cleared the bar. Back-to-school season and wider sales coverage can boost prescriptions, but the underwriting test is whether new-to-brand demand persists after the seasonal peak and translates into net revenue without materially higher rebates. Azstarys’ early return to prescription growth is encouraging, but management supplied no 2027 growth target and its gross-to-net trajectory remains unproven.

Pain deterioration has a second-order effect: it reduces the internally generated cash available to fund ADHD promotion, debt reduction, and buybacks. The ASR may support near-term per-share optics, but it does not resolve that cash-flow dependency; at roughly 2x net leverage, sustained erosion would narrow capital-allocation flexibility. Conversely, the Jan. 1 Xtampza formulary change could improve access, though exclusivity is not equivalent to profitable volume if concessions rise.

Near term, the market may reward ADHD mix shift and affirmed guidance. Over 1–3 months, Q4 prescription conversion and net sales are the test; over 6–18 months, Azstarys growth, pain cash-flow durability, and Belbuca generic risk matter more. The transcript contains inconsistent Jornay revenue figures; verify against the filing before using product-level revenue estimates. No valuation or price context is supplied, so the evidence supports a conditional watch rather than an unconditional chase. Thesis weakens if ADHD growth stalls or adjusted EBITDA guidance is cut; it strengthens if prescriptions convert to revenue while gross-to-net remains controlled.

Key Decisions for Investors

• COLL: Prefer buying weakness rather than chasing the earnings reaction. Reassess after Q4 results for continued new-to-brand prescription momentum and Azstarys growth alongside net revenue; do not underwrite an expansion in valuation without evidence that growth survives seasonality.
• Track quarterly ADHD gross-to-net, prescription-to-revenue conversion, and adjusted EBITDA against guidance. Rising prescriptions with weak net-sales conversion or EBITDA deterioration would indicate that commercial investment and rebates are consuming the mix-shift benefit.
• Treat the Xtampza formulary move as a catalyst to monitor, not booked upside: verify covered-life access translates into prescription growth without margin-dilutive concessions. Watch for Teva ANDA approval, published pricing, or wholesaler contracting ahead of the Jan. 23, 2027 Belbuca settlement date; absent those signals, avoid positioning for an imminent generic launch.